The Best Collaboration in Creating Greatness

;

Partnering to Bring Cardiovascular Treatments to Patients Around the World

At Amarin, we believe in taking BOLD steps to help patients globally, that by joining with others we can reach our goals faster. Building alliances with complementary partners underlies our accomplishments to date and will help enhance our potential future successes. Amarin seeks to leverage its core strengths by collaborating with others to create value. Toward that end, Amarin has a network of experienced commercial partners for our products in focused geographies around the world where we do not intend to create our own commercial teams. This important prescription drug is currently marketed and sold through commercial partners in numerous key markets throughout the world with submissions seeking approval under regulatory reviews in numerous other countries around the world. In addition, Amarin is partnered with a network of highly capable and reliable manufacturers to ensure the highest quality production.

Why Partner with Amarin?

  • Track record of successful collaboration with medical, scientific and academic leaders, institutions and companies throughout the world
  • Broad success in securing payer coverage through managed care
  • Significant commercial footprint in the United States with sales teams calling on key customers
  • Demonstrated commitment to improving patient care and improving the value
  • Positive reputation for integrity, follow-through and innovation

Coming together for cardiovascular care

Want to know more about how great partnerships in cardiometabolic care is built? Read below for press releases, articles and more relating to our business associates.

2025-06-24
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VA...
2025-05-07
Amarin Reports First Quarter 2025 Financial Results
2025-04-29
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
2025-04-28
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2...
2025-04-09
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
2025-04-07
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
2025-03-31
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosa...
2025-03-19
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lip...
arrow left icon
arrow right icon

Business Inquiries Form

Companies that align with Amarin’s goals are encouraged to consider providing capabilities and proposals. If you are an innovative high-quality company that would like to partner with us, complete the contact form

Leadership

With decades of expertise in the cardiometabolic & pharma industry, we're committed to Amarin’s BOLD mission.

Company Profile

A rapidly growing, international leader in the fight to address cardiovascular disease

Amarin focuses on a BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide.

Investor Relations

A BOLD investment in cardiometabolic health

Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.

Science and Health

Passionate about cardiometabolic science and health

Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.

Working at Amarin

A BOLD place for entrepreneurial careers

Are you interested in joining Amarin and being part of our BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide? Click here for more information about our culture, career opportunities, benefits and more.

ALL-NP-00015 1/23